← Back to Search

Behavioral Intervention

Mindfulness Practices for ADHD

N/A
Recruiting
Research Sponsored by University of Alabama, Tuscaloosa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 17-25
Be younger than 65 years old
Must not have
Unstable dosage of psychotropic medication
Psychotic symptoms
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment, up to 1-month post-treatment, 6-month follow-up
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a mindfulness intervention to help college students with ADHD. If successful, it could have a large impact on public health.

Who is the study for?
This trial is for first-year college students aged 17-25 who have been diagnosed with ADHD. Participants should not have major medical issues or severe mental health conditions like depression, mania, substance abuse, personality disorders that could affect group participation, psychosis, recent trauma, or unstable psychotropic medication doses.
What is being tested?
The study is testing a mindfulness program adapted for ADHD against the usual services provided to these students. It aims to see if this approach is practical and helpful in managing ADHD symptoms among first-year college students.
What are the potential side effects?
Since the intervention involves mindfulness practices rather than medication, side effects are minimal but may include temporary increases in emotional discomfort as individuals become more aware of their thoughts and feelings.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 17 and 25 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My mental health medication dose has been changing.
Select...
I have experienced symptoms like hallucinations or delusions.
Select...
I have severe depression.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment, up to 1-month post-treatment, 6-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment, up to 1-month post-treatment, 6-month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adult Concentration Inventory
Attention Network Task
Conners Adult ADHD Rating Scale
+6 more
Secondary study objectives
Behavior Rating Inventory of Executive Function - Adult Version
Grade Point Average
Social Functioning Questionnaire
Other study objectives
Implementation Quality Measure
Session Checklist and Therapist Feedback Form
Treatment Satisfaction and Acceptability Questionnaire

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Adapted Mindful Awareness Practices (MAPS)Experimental Treatment1 Intervention
The Mindful Awareness Practices (MAPs) for ADHD program, an 8-week, group-based mindfulness program for adults with ADHD, has been shown to reduce ADHD, depression, and anxiety symptoms. While promising, it is unknown as to whether the MAPs protocol is feasible, acceptable, and efficacious for college students with ADHD. The current study takes the first step towards enhanced study of mindfulness for college students with ADHD by testing the feasibility, acceptability, and preliminary efficacy of an adapted MAPs protocol delivered within university counseling center settings during the first semester of college.
Group II: Services-As-UsualActive Control1 Intervention
Services-As-Usual includes the standard academic support services provided by university disability/accessibility offices.

Find a Location

Who is running the clinical trial?

Wofford CollegeUNKNOWN
University of Alabama, TuscaloosaLead Sponsor
46 Previous Clinical Trials
17,478 Total Patients Enrolled
~50 spots leftby May 2026